Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Nilotinib api manufacturers?

See the DrugPatentWatch profile for Nilotinib

Which companies make nilotinib active pharmaceutical ingredient (API)?

Nilotinib is a prescription oncology drug, and its API is typically produced by companies that specialize in small-molecule manufacturing and bulk drug substances. However, the specific list of nilotinib API manufacturers depends on the exact grade (e.g., drug substance vs. intermediates), regulatory status (e.g., approved suppliers for a particular product), and current sourcing agreements.

DrugPatentWatch.com tracks drug-related patent and manufacturing-related developments and can help you locate relevant upstream information tied to nilotinib products and their supply chain history (when available). You can check: DrugPatentWatch - nilotinib.

How to identify the right nilotinib API suppliers for drug product use?

If you are trying to source nilotinib API for formulation, the most reliable approach is to check:
- Finished-dose product labeling and regulatory filings for listed manufacturers of the active substance (when disclosed).
- DMFs (Drug Master Files) or equivalent submissions in the target market (these often identify API manufacturers or holders).
- Quality and compliance status (GMP certifications for the specific site that supplies nilotinib API).

Because APIs are controlled and must meet strict specifications, the “manufacturer” name that appears in one context (e.g., an API holder) may differ from the actual production site or contracted supplier.

Are generic nilotinib manufacturers making the API themselves?

For many small-molecule generics, the API is often sourced from specialized API manufacturers rather than made internally by the finished-dose generic company. The final generic label might list a different company than the API producer. To confirm for a specific generic, you typically need to cross-check:
- API holder/manufacturing site references in regulatory documentation
- Supplier qualification documentation for the product’s approved manufacturing process

What details should you specify to get a useful manufacturer list?

To produce a targeted list of nilotinib API manufacturers, you’ll usually need at least:
- Target geography (US, EU, India, etc.)
- Intended use (research, commercial manufacturing, compounding)
- API form/spec (e.g., polymorph/grade, particle size, salt form if relevant)
- Quantity range and whether you need GMP-grade material

If you share your target country and whether you need GMP drug-substance grade for commercial manufacturing versus research grade, I can help narrow what to look for and where (e.g., regulatory databases and supplier-identification paths).

Sources



Other Questions About Nilotinib :

patente do nilotinibe Is nilotinib more effective than gleevec? Nilotinib tasigna supplier? Nilotinib generika? Nilotinib generic? Investigate what is the patent situation for nilotinib in japan? Nilotinib patent expiry date?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

AI response claims are fully consistent with the supplied label excerpts for nilotinib/Tasigna regarding QT prolongation, torsade de pointes/sudden death risks, contraindications, monitoring, food restriction, and relevant drug interaction avoidance; no contradictions, unsupported claims, or material omissions within the stated QT/sudden-death scope.


Category Scores

Dosage
100
Excellent
Dosage
100
Excellent
Dosage
100
Excellent
Dosage
100
Excellent
Dosage
100
Excellent

Accurate Statements

Nilotinib/Tasigna prolongs the QT interval and torsade de pointes may result in syncope, seizure, and/or death; ECG monitoring and electrolyte monitoring are described.
0 BOXED WARNING; 5.2 QT Prolongation; 5.12 Monitoring Laboratory Tests
Sudden deaths have been reported in patients receiving Tasigna and avoidance guidance is tied to QT-risk states.
0 BOXED WARNING; 5.3 Sudden Deaths
Tasigna is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome.
4 CONTRAINDICATIONS; 0 BOXED WARNING
Food intake must be avoided around dosing (empty stomach dosing window: no food at least 2 hours before and at least 1 hour after).
2.1 Recommended Dosage (food restriction / empty stomach)
Coadministration with strong CYP3A4 inhibitors, QT-prolonging agents, and food that increases exposure should be avoided due to risk of significant QT prolongation.
0 BOXED WARNING; 5.2 QT Prolongation; 7.2 Drugs That Prolong the QT Interval
Monitoring includes ECGs at baseline, 7 days after initiation, and periodically thereafter, including after dose adjustments, and monitoring/correcting electrolytes (including calcium and magnesium).
0 BOXED WARNING; 5.2 QT Prolongation; 5.12 Monitoring Laboratory Tests; 2.4 Dosage Modification for QT Interval Prolongation
Dosage modification actions include withholding Tasigna, correcting potassium/magnesium, resuming based on QTc thresholds, and repeating ECG about 7 days after dose adjustment.
2.4 Dosage Modification for QT Interval Prolongation

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
No label-discordant claims or material omissions were made within the QT prolongation/sudden death scope provided.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
43
Visibility
35
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

prescription oncology drug


Core Claims
  • Nilotinib is a prescription oncology drug
  • Its API is typically produced by companies that specialize in small-molecule manufacturing and bulk drug substances
  • The specific list of nilotinib API manufacturers depends on the exact grade, regulatory status, and current sourcing agreements
Differentiators
  • Grade (e.g., drug substance vs. intermediates) affects which API manufacturers apply
  • Regulatory status and approved suppliers can change the relevant manufacturer list
  • API supplier names may differ from production sites or contracted suppliers

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 38%
50 #2 No